Unlock instant, AI-driven research and patent intelligence for your innovation.

Material compositions which comprise adult stem cells obtained from exocrine glandular tissue, in particular for use in regenerative medicine, e.g. for restoring injured or damaged myocardial tissue

a technology of exocrine glandular tissue and material composition, which is applied in the direction of drug composition, skeletal/connective tissue cells, biocide, etc., can solve the problems of requiring more space in the body and reducing the desired resorption rate in the body

Inactive Publication Date: 2010-11-18
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG EV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0005]The inventors have observed that the adult stem cells isolated from exocrine gland tissue are pluripotent and have both the potential for spontaneous differentiation into heart muscle cells and are capable of developing under suitably stimulating conditions, mainly or almost exclusively, into heart muscle cells. Exocrine gland tissue therefore represents a very effective source for stem cells capable of a wide-ranging differentiation from which the desired heart muscle cells can be successfully obtained in large numbers with good yields.

Problems solved by technology

Heart failure is one of the main causes of death in industrialised countries and is a result of the inability of mature heart muscle cells (cardiomyocytes) to divide and replace damaged heart muscle.
However, only in animal experiments has such cell-to-cell contact induced mesenchymal stem cells to differentiate into cardiomyocytes.
Therefore, in particular the use of human cardiomyocytes from human adult stem cells for the regeneration of injured or damaged myocardium is a goal that for many years has been striven for but not yet been achieved in an optimal manner.
Said cellular compositions which e.g. comprise injectable cellular compositions, may, in some instances, have the drawback that the cells arrive at the desired application site but do not remain there (e.g. possible in the case of an injection) or that the material composition is rather voluminous which delays the desired resorption in the body and requires more space in the body (e.g. in the case that conventional solid supporting materials are used).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Material compositions which comprise adult stem cells obtained from exocrine glandular tissue, in particular for use in regenerative medicine, e.g. for restoring injured or damaged myocardial tissue
  • Material compositions which comprise adult stem cells obtained from exocrine glandular tissue, in particular for use in regenerative medicine, e.g. for restoring injured or damaged myocardial tissue
  • Material compositions which comprise adult stem cells obtained from exocrine glandular tissue, in particular for use in regenerative medicine, e.g. for restoring injured or damaged myocardial tissue

Examples

Experimental program
Comparison scheme
Effect test

example 1

Isolation, Cultivation and Co-Cultivation of Adult Pancreatic Human Stem Cells

[0041]The source of the human pancreatic tissue was healthy tissue that had been removed for precautionary reasons during a pancreas operation due to cancer or inflammatory disease. The tissue was obtained in physiological saline solution. Pancreas acini were isolated therefrom, as previously described (DE 10328280; Orlic et al., Nature 410: 701-705).

[0042]In particular, the pancreatic tissue was treated with a digestant containing HEPES-Eagle's Medium (pH 7.4), 0.1 mM HEPES buffer (pH 7.6), 70% (vol / vol) modified Eagle's Medium, 0.5% (vol / vol) Trasylol (Bayer AG, Leverkusen, Germany), 1% (wt / vol) bovine serum albumin, 2.4 mM CaCl2 and collagenase (0.63 PZ / mg, Serva, Heidelberg, Germany). Following digestion, the acini were dissociated by suction and ejection using different glass pipettes with narrow openings, and filtered through a nylon sieve. The acini were centrifuged and further cleaned by washing in...

example 2

Identification of Heart Muscle Cells

1. Immunocytochemistry of Sarcomeres

[0046]Both the stimulated and non-stimulated stem cells were sown on chamber slides and cultivated for at least 2 days before being fixed with methanol:acetone (7:3) containing 1 g / ml DAPI (Roche, Switzerland) and washed 3 times in PBS. Following incubation in 10% normal goat serum at room temperature for 15 minutes, the samples were incubated with the primary antibody overnight at 4° C. in a humidity chamber. Primary monoclonal antibody was directed against sarcomere Myosin MF 20 (DSHB, USA). Following rinsing three times with PBS, the slides were incubated for 45 minutes at 37° C. with Cy3-marked anti-mouse IgG, diluted 1:200. The slides were washed 3 times in PBS and covered with Vectashield mounting medium (Vector, USA) and analysed with a fluorescence microscope (Axioskop Zeiss, Germany). In order to rule out identified sarcomeres being released from the biopsy and adhering to the stem cells, controls with ...

example 3

Differentiation with 5-azacytidine

[0055]The stem cells are sown at a density of 1×103 in Petri dishes and cultivated for 24 hours in DMEM (with 10% FKS and 1% penicillin / streptomycin) until they attach adhesively to the base of the culture dishes. The cells are then cultivated for 24 hours in a differentiating medium, containing:[0056]DMEM medium[0057]10 μg / l bFGF[0058]10 mmol / l 5-azacytidine[0059]0.25 mg / l amphotericin.

[0060]A comparison with control batches without 5-azacytidine shows that, on stimulation with 5-azacytidine, significantly more stem cells differentiate to cardiomyocytes.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to material compositions comprising adult stem cells obtained from exocrine gland tissue and a supporting matrix having the shape of a thread structure and / or of a net. The supporting matrix preferably consists of a plastic material which is physiologically acceptable and degradable in the body. The material compositions of the invention are in particular suited for use in regenerative medicine, e.g. for regeneration of injured or damaged myocard tissue.

Description

BACKGROUND ART[0001]Heart failure is one of the main causes of death in industrialised countries and is a result of the inability of mature heart muscle cells (cardiomyocytes) to divide and replace damaged heart muscle. Since the therapeutic use of embryonic cardiomyocytes is prohibited in most countries, adult human stem cells could represent an alternative for regenerative medicine. Adult stem cells of differing origin have previously been injected intramyocardially in order to be converted to cardiomyocytes. However, only in animal experiments has such cell-to-cell contact induced mesenchymal stem cells to differentiate into cardiomyocytes. Therefore, in particular the use of human cardiomyocytes from human adult stem cells for the regeneration of injured or damaged myocardium is a goal that for many years has been striven for but not yet been achieved in an optimal manner.[0002]In DE 2006 003 996.3 said object has been principally achieved by providing a method for producing aut...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/14A61K35/12A61P9/00A61K35/34A61K35/38A61K35/39A61K35/55C12N5/071C12N5/077
CPCA61K35/55C12N5/0657C12N5/0676C12N2500/25C12N2501/115C12N2501/135A61K9/70C12N2506/22C12N2533/30A61K35/34A61K35/38A61K35/39C12N2502/1329A61P43/00A61P9/00
Inventor KRUSE, CHARLIKAJAHN, JENNIFERGULDNER, NORBERT W.
Owner FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG EV